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Abstract
Background: Chronic myocarditis is often initiated by viral infection, the most common of which is coxsackievirus infection.
The precise mechanism by which viral infection leads to chronic autoimmune pathology is poorly understood, however it is
clear that the early immune response plays a critical role. Previous results have shown that the inflammatory cytokine
interleukin (IL)-6 is integral to the development of experimental-induced autoimmune myocarditis. However, the function of
IL-6 during viral-mediated autoimmunity has yet to be elucidated.
Methods and Results: To address the requirement of IL-6 during disease induction, IL-6 deficient mice were infected with
coxsackievirus B3 (CB3). Following infection, mice lacking IL-6 developed increased chronic autoimmune disease pathology
compared to wild type controls without a corresponding change in the level of viral replication in the heart. This increase in
disease severity was accompanied by elevated levels of TNF-a, MCP-1, IL-10, activated T cells and cardiac infiltrating
macrophage/monocytes. Injection of recombinant IL-6 early following infection in the IL-6 deficient mice was sufficient to
lower the serum cytokines TNF-a and IL-10 as well as the serum chemokines MCP-1, MIP-1b, RANTES and MIG with a
corresponding decrease in the chronic disease pathology strongly suggests an important regulatory role for IL-6 during the
early response.
Conclusions: While IL-6 plays a pathogenic role in experimental-induced autoimmune disease, its function following viral-
induced autoimmunity is not reprised. By regulating the early immune response and thereby controlling the severity of
chronic disease, IL-6 directs the outcome of chronic autoimmune myocarditis.
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Introduction
Autoimmune myocarditis, a precursor stage of dilated cardio-
myopathy (DCM), is the leading cause of sudden death in young
adults [1]. Disease progression to DCM leaves heart transplanta-
tion as the only treatment option. DCM is often caused by
enterovirus infection, predominantly the cardiotropic virus
coxsackievirus [1]. Following coxsackievirus B3 (CB3) infection,
an acute disease stage ensues in which heart damage is viral-
mediated. In genetically susceptible individuals, disease can
progress to a chronic autoimmune phase characterized by
infiltration of autoreactive lymphocytes and fibrosis of the heart
tissue. While the mechanism by which viral infection leads to
autoimmune myocarditis is not completely understood, there is
compelling evidence to suggest that interleukin (IL)-6 is involved
[2,3,4,5].
IL-6 is a pleotropic cytokine that acts during both pro- and anti-
inflammatory responses and has been observed in the context of
infection, inflammation and autoimmunity. IL-6 is typically
induced following pathogen stimulation as a part of the innate
inflammatory response and its major functions include initiation of
the acute-phase response, activation of T cells and stimulation of B
cell immunoglobulin production [6]. More recently, IL-6 has been
linked to the release of otherwise suppressed effector T cells [7],
inhibition of TGF-b induced regulatory T (Treg) cell generation
[8] and induction of Th17 cells as a co-factor with TGF-b [9].
Further, signaling through gp130, a component of the IL-6
receptor complex, protects cardiac myocytes from CB3 infection
directly [10]. IL-6 functions globally in response to inflammation
and infection and it is important in our understanding of the
development of autoimmunity.
Specifically, lack of IL-6 has been demonstrated to be sufficient
to prevent a plethora of autoimmune diseases such as experimental
autoimmune encephalomyelitis (EAE) [11], pristane-induced lupus
[12], experimental-induced arthritis [13,14], autoimmune myas-
thenia gravis [15] and, most notably with regard to this report,
experimental-induced autoimmune myocarditis (EAM) [2]. Fol-
lowing injection of cardiac myosin peptide emulsified in complete
Freund’s adjuvant (CFA), EAM did not develop in IL-6 deficient
mice (IL-6KO, BALB/c) [2]. IL-6KO mice had decreased levels
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cules following induction of disease. While EAM is a useful model
of myocarditis that allows for study of the chronic stage of disease
without the complication of the viral infection, it does not mimic
the natural acquisition of disease and lacks the complexity of the
response to virus. Thus, it is valuable to decipher the role of IL-6
in the context of viral-induced autoimmune myocarditis.
In this report, we demonstrate that IL-6 regulates the
development of CB3-mediated chronic myocarditis. In contrast
to the EAM findings, IL-6KO mice infected with CB3 developed
significantly greater chronic heart disease. Heightened disease was
associated with increases in early inflammatory responses
including serum levels of TNF-a, IL-10 and MCP-1 as well as T
cell activation and cardiac monocyte/macrophage infiltration.
The early inflammatory response and chronic disease severity was
controlled by supplementing the viral infection with recombinant
IL-6 indicating that IL-6 functions as a regulator of the early host
response and has a protective role during the progression of CB3-
induced chronic myocarditis.
Materials and Methods
Animals
IL-6 deficient C57BL/6 (IL-6KO) and C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). These
mice were maintained in the Wesbrook Animal Facility at the
University of British Columbia (UBC).
Virus
Coxsackievirus group B type 3 (CB3) (Nancy strain) was
obtained from Dr. J.K. Chantler (UBC). Virus stocks of CB3 were
prepared as previously described [16]. Virus stocks were stored at
280uC. Mice 8–12 weeks of age were infected intraperitoneally
with a sublethal dose of 100 PFU of CB3 in Dulbecco’s Modified
Eagle Medium (DMEM) for the initial experiments. Subsequently,
mice were infected with 10,000 PFU of CB3 in DMEM and this
includes the rIL-6 addition experiments.
The IL-6KO mice are only commercially available on the
C57BL/6 background which is genetically resistant to CB3-
induced chronic autoimmune myocarditis, therefore, co-treatment
with LPS at the time of infection is required to overcome genetic
resistance [17]. C57BL/6 and IL-6KO mice were treated with
CB3, CB3 plus 25 mg LPS (S. minnesota) (CB3/LPS), 25 mg LPS (S.
minnesota) (Sigma-Aldrich, St. Louis, MO) or DMEM. Mice were
sacrificed at day 10 (acute phase) or day 28 (chronic phase) post
infection. Where noted, mice were injected with 50 ng/mouse
recombinant mouse IL-6 (rIL-6) (eBioscience, San Diego, CA) or
DMEM at days 0, 1, 2 and 3 post treatment with CB3/LPS.
Quantitation of the replicative virus in the heart
Viral load was quantitated by plaque assay at day 5 post
infection. Heart samples were collected, weighed and homoge-
nized at 10% weight/volume in DMEM. Dilutions of homoge-
nates were incubated at 37uC with rocking for one hour on a
confluent monolayer of HeLa cells (ATCC CCL-2). Plates were
incubated for three days to allow plaque formation. Plaque assays
were performed in duplicate.
Histology
At sacrifice, heart tissue was removed for paraffin sectioning.
Tissue was processed and stained by Wax-it Histology Services Inc.
(UBC). Sections of 4 micron thickness were cut for staining. Tissue
was stained by standard protocols with hematoxylin and eosin as
well as Masson’s trichrome to detect damage by cellular infiltration
and fibrosis. Serial sections of the heart were scored blindly
according to a 4-tier scoring system: grade 1, 0–10% pathology;
grade 2, 11–25%; grade 3, 26–50%; grade 4, greater than 50%.
Flow cytometry
At sacrifice, spleen tissue was removed and placed in phosphate
buffered saline (PBS) buffer on ice. Single cell suspensions of
splenocytes were isolated by standard procedures. Cells were
treated with Mouse BD FcBlock
TM (clone 2.4G2) (BD Pharmin-
gen, San Jose, CA) for 15 minutes prior to staining. Flow
cytometry was performed on a FACS Calibur or a LSRII (BD
Biosciences, San Jose, CA) and analysed with FlowJo (Tree Star
Inc., Ashland, Oregon) software.
Antibodies
The following antibodies were purchased from BD Pharmingen:
biotin-anti-CD69 (clone H1.2F3), biotin-anti-CD44 (clone IM7),
biotin-anti-CD49b (clone DX5), biotin-anti-CD3 (clone 145-
2C11), biotin-anti-CD62L (clone MEL-14), APC-anti-CD11b
(clone M1/70), biotin-anti-CD80 (clone 16-10A1), biotin-anti-
CD86 (clone GL1) and biotin-anti-CD40 (clone 3/23). The
following antibodies were purchased from eBioscience: APC-anti-
CD4 (clone RM4-5), FITC-anti-CD8 (clone 53–6.2), FITC-anti-
Foxp3 (clone FJK-16s), PE-anti-RORct (clone AFKJS-9), PE-anti-
CD25 (clone PC61), FITC-anti-CD11c (clone N418), biotin-anti-
CD14 (clone Sa2-8) and biotin-anti-F4/80 (clone BM8). Hamster
IgG1l (BD Pharmingen), rat IgG2aK (BD Pharmingen) and rat
IgG2a (eBioscience) were used as isotype controls for CD69,
Foxp3 and RORct staining respectively. Streptavidin-PE (BD
Pharmingen) or Streptavidin-PECy-7 (eBioscience) were used as
secondary antibody to visualize biotinylated antibodies.
Cytometric bead array
Serum was collected at days 1, 3, 7 and14 post treatments with
DMEM, LPS, CB3 or CB3/LPS and stored at 280uC until
analysis. Concentrations of TNF-a, IFN-c, IL-6, IL-12p70, IL-10
and MCP-1 were determined with a BD Cytometric Bead Array
(CBA) Mouse Inflammation kit according to manufacturers’
instructions (BD Biosciences). Concentrations of MIP-1a, MIP-
1b, MIG and RANTES were determined from serum samples
collected at day 3 post CB3/LPS treatment with rIL-6 or DMEM
treatment at days 0, 1 and 2 PI using a BD CBA flex set kit
according to manufacturers’ instructions (BD Biosciences). Data
was analyzed with FCAP Array software (BD Biosciences).
Isolation of heart infiltrate
Mice were anesthetized with 3.2 mg Ketalean (Bimeda-MTC,
Dublin, Ireland) and 0.08 mg Xylazine (Bayer, Leverkusen,
Germany) and perfused with sterile PBS at 7 or 10 days post
CB3/LPS treatment. Hearts were minced and digested with 0.2%
collagenase (Sigma-Aldrich), 0.25% pancreatin (Sigma-Aldrich)
and 0.1% DNase (Roche Applied Science, Basel, Switzerland) for
7 minutes at 37uC. Digestion was stopped with addition of 0.1M
EDTA. Following digestion, single cell suspensions of heart
infiltrate were isolated by standard procedures and cells were
stained for flow cytometry.
Statistics
Statistical analysis was done by unpaired Student’s t-test for all
plaque assay, cytokine analysis and immune cell population
analysis. P values of ,0.05 (*) were considered significant. Mann
Whitney U test was used to calculate significance for differences in
disease severity.
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Increased severity of chronic myocarditis in IL-6KO mice
To determine the role of IL-6 in the viral induction of
autoimmune myocarditis, myocarditis was induced in IL-6KO
and wild type C57BL/6 (wt) mice by injection of CB3 plus LPS (S.
minnesota) (CB3/LPS). Control mice were concurrently challenged
with CB3, LPS (S. minnesota) alone or DMEM. Heart tissue from
mice sacrificed at day 10 PI showed pathology characteristic of the
acute phase of myocarditis in both C57BL/6 and IL-6KO mice
treated with CB3/LPS (Figure 1a). Acute disease pathology was not
observed in IL-6KO mice treatedwithLPS or CB3 alone indicating
that, as with wt mice, disruption of IL-6 does not alter the general
immune response enough to allow LPS or CB3 alone to cause
disease (Figure 1a). Heart tissue harvested from mice at day 28 PI
showed fibrosis and immune cell infiltration characteristic of
Figure 1. IL-6KO mice develop increased chronic myocarditis severity without an increase in virus in the heart. (A) Representative
Hematoxylin and Eosin stained cardiac sections from C57BL/6 or IL-6KO mice. Mice treated with LPS or CB3 alone did not develop acute disease
lesions at day 10 PI (LPS: C57BL/6 n=4, IL-6KO n=4) (CB3: C57BL/6 n=5, IL-6KO n=4). Mice treated with CB3/LPS developed lesions and immune cell
infiltration at 10 days PI (C57BL/6 n=4, IL-6KO n=4). Magnification:4006. (B) Representative Masson’s Trichrome stained cardiac section from C57BL/
6 or IL-6KO mice. Following treatment with CB3/LPS, mice developed disease pathology as determined by fibrosis in blue and immune cell infiltration
within the fibrosis areas by 28 days PI (C57BL/6 n=15, IL-6KO n=20). Mice infected with LPS or CB3 alone did not develop significant chronic disease
pathology (LPS: C57BL/6 n=5, IL-6KO n=5) (CB3: C57BL/6 n=6, IL-6KO n=7). Magnification:4006. (C) Chronic cardiac disease histology was scored
blindly by a four tier grading system to determine severity differences: grade 1, 0–10% pathology; grade 2, 11–25%; grade 3, 26–50%; grade 4, greater
than 50% (black circles indicate wt mice, white circles indicate IL-6KO mice) (bar is mean6SE, *p,0.05). Disease severity was found to be significantly
higher in the IL-6KO mice compared to wild type controls. (D) Quantification of replicative virus in the heart post infection showed no significant
differences in viral titer between IL-6KO and wt mice at day 5 post infection (CB3: C57BL/6 n=5, IL-6KO n=5) (CB3/LPS: C57BL/6 n=5, IL-6KO n=5)
(black bars indicate wt mice, white bars indicate IL-6KO mice) (mean6SE, NS=not significant). This indicates that IL-6 is not essential for control of
viral replication in the heart.
doi:10.1371/journal.pone.0006207.g001
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CB3/LPS (Figure 1b) indicating the IL-6 is not required for chronic
myocarditis development. This chronic disease was autoimmune in
nature as transfer of splenocytes from CB3/LPS treated IL-6KO
mice into naı ¨ve RAG deficient mice was sufficient to induce disease
(Data not shown). As expected, mice treated with CB3, LPS or
DMEM alone showed no signs of chronic myocarditis or fibrosis at
day 28 (Figure 1b, Data not shown).
Comparison of chronic disease severity between the IL-6KO
mice and wt controls showed significantly greater disease
pathology in IL-6KO mice as compared to wt mice (Figure 1c).
Over 65% of IL-6KO mice presented with infiltrating lesions and
fibrosis with grade 4 severity, while 93% of wt mice had grade 2 or
less heart pathology. Therefore, lack of IL-6 results in greater
chronic disease severity post-infection and is indicative of a
regulatory role for IL-6 in the host response to infection and the
ensuing chronic pathology.
Cardiac viral replication in IL-6KO mice is similar to wt
controls
The increased cardiac disease pathology observed in IL-6KO
mice could be a direct result of the inability to control viral
infection in the heart. To determine whether differences in viral
numbers were responsible for the increased pathology, quantita-
tive viral plaque assays were performed. No significant difference
in the replicating viral numbers in the heart was observed between
IL-6KO and wt mice at day 5 PI (Figure 1d). This suggests that the
differences in disease severity were not a direct result of an inability
of IL-6KO mice to control cardiac infection.
Increased CD69 expression by T cells in CB3-infected IL-
6KO but not in wt mice
Toexaminewhetherchangesintheantigenpresentingcells(APC)
or the T cell response following infection were responsible for the
increase in disease severity,ananalysisof immune cellspost-infection
was performed. No differences were observed in the percentages of
immune cell populations present as measured by APC markers
CD11b and CD11c or the T cell co-receptors CD4 and CD8.
Within these cell populations, no differences in activation state were
observed as measured by the APC co-stimulatory markers CD80,
CD86 or CD40 or the T cell activation markers CD44, CD62L or
CD25 (Data not shown). However, in IL-6KO mice, the T cell
activation marker, CD69, was significantly upregulated on both
CD4+ and CD8+ T cells at day 3 PI as compared to wt controls
(Figure 2a, Figure S1). By day 7 however, this difference in CD69
expressionhad diminished andwassimilarto thatfound onT cellsin
wt mice (Figure 2a, Figure S1). As CD69 is the only activation
marker to be upregulated in the IL6KO mice, the increase in
CD69+ cells reflects an important early T cell regulatory role for IL-
6 and these cells may be integral to the increase in disease severity.
Based on data suggesting that IL-6is important in Treg induction
and function [7,8], we monitored changes in Treg cell populations
over the course of infection. Tregs were identified using the cell
markers CD4, CD25 and the Treg specific transcription factor,
Foxp3. While the steady state ratio of Treg cells to CD4+
lymphocytes was found to be significantly lower in the IL-6KO
mice compared to wt mice, following disease induction the ratio of
Treg cells to CD4+ T cells did not significantly differ (Figure 2b,
Figure S2). This suggests that there is likelya sufficient proportion of
Treg cells present to regulate the T cell response following infection
and we found no evidence to suggest that lack of IL-6 resulted in
changes in the Treg population that influenced the severity of
pathology observed post-infection in the heart.
Early upregulation of MCP-1, TNF-a and IL-10 in IL-6KO
mice
To determine if changes in the inflammatory response post-
infection are responsible for the differences in disease severity,
serum was assayed post infection using the BD CBA kit to measure
inflammatory cytokine levels. Serum was collected at 1, 3, 7 and
14 days PI and assayed for TNF-a, IFN-c, IL-6, IL-12p70, IL-10
and MCP-1 (Figure 3). In response to CB3 infection, wt mice, but
not IL-6KO mice, upregulated IL-6 with a peak in production at
day 3 post infection indicating that IL-6 is involved in the early
immune response following coxsackievirus infection (Figure 3).
IFN-c and IL-12p70 levels increased at a similar rate in both IL-
6KO and wt controls following CB3/LPS treatment (Figure 3).
However, the levels of TNF-a, IL-10 and MCP-1 were increased
in IL-6KO mice compared to the wt controls (Figure 3). TNF-a
upregulation occurred following CB3/LPS and LPS treatment in
wt mice and CB3/LPS, CB3 and LPS treatment in the IL-6KO
mouse. An additive effect with CB3 and LPS treatment was
observed only in the absence of IL-6. Conversely, increased IL-10
production in IL-6KO mice corresponded to the presence of LPS
as levels were elevated following LPS or CB3/LPS treatment.
This was only observed in the absence of IL-6. This strongly
suggests that production of the immunosuppressive cytokine IL-
10 is regulated in part by IL-6. The change in MCP-1 levels in
IL6KO mice corresponded to viral infection as both CB3 and
CB3/LPS treatment resulted in increased production whereas
LPS treatment alone did not. This suggests that MCP-1 is
regulated by IL-6 following CB3 infection. Taken together, these
results suggest that in the absence of IL-6, there is an imbalance
in the induction of early inflammatory modulators and that IL-6
likely functions as a regulator of the early immune response to
infection.
Increased cardiac infiltration of macrophage/monocytes
in CB3-infected IL-6KO mice
Increased levels of the chemokine MCP-1 have previously been
associated with increased migration of mononuclear cells to the
heart at 7 days post CB3 infection [18]. To determine if the
heightened disease severity and MCP-1 production in IL-6KO
mice reflected an increase in mononuclear cell infiltration in the
heart during the initiation of disease, flow cytometry was used to
directly characterize the immune cells infiltrating the heart (day 7
PI). Significant increases in the infiltration of monocyte/macro-
phages, as determined by forward and side scatter and based on
surface expression of CD11b and CD11c, was observed in the
hearts of IL-6KO mice treated with CB3/LPS as compared to
their wt counterparts (Figure 4, Figure S3). These CD11b+ cells
were further determined to be 81.3%61.1% F4/80 positive and
59.7%62.8% CD14 positive identifying them as primarily
monocyte/macrophages. No other significant difference in the
immune cell infiltration was observed (Data not shown). This
demonstrates that greater cardiac infiltration by macrophage/
monocytes occurred in association with an increase in chronic
disease severity following infection of IL-6KO mice. This strongly
suggests that heightened MCP-1 levels in the absence of IL-6 leads
to greater immune cell infiltration, specifically CD11b+ cells, and
subsequent cardiac pathology.
Recombinant IL-6 treatment in IL-6KO mice results in
decreased chronic disease severity
The increased autoimmune disease observed in IL-6KO mice
could be due to an early developmental defect in these mice rather
than a lack of IL-6 specifically during the early immune response.
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response regulates the chronic disease severity, recombinant IL-6
(rIL-6) or DMEM was administered to IL-6KO mice at days 0, 1,
2 and 3 PI and the chronic disease severity was observed at 28
days PI. IL-6KO mice were found to have significantly increased
chronic disease severity compared to wild type controls, however,
treatment with rIL-6 was sufficient to decrease the chronic disease
histology (Figure 5a and 5b). This conclusively shows that IL-6
regulates chronic disease severity by regulating the early immune
response following viral infection.
Figure 2. IL-6KO mice have increased expression of the early activation marker CD69 at 3 days PI. (A) T cell activation was monitored by
flow cytometry analysis of splenocytes following DMEM, LPS, CB3 or CB3/LPS treatment. Activated T cells were identified by the surface markers CD4,
CD8 and CD69. CD69 expression was significantly increased on both CD4+ and CD8+ T lymphocytes at 3 days post infection (DMEM: C57BL/6 n=4,
IL-6KO n=4) (LPS: C57BL/6 n=7, IL-6KO n=8) (CB3: C57BL/6 n=8, IL-6KO n=18) (CB3/LPS: C57BL/6 n=8, IL-6KO n=17) (black bars indicate wt mice,
white bars indicate IL-6KO mice) (mean6SE, *p,0.05) and abrogated by 7 days post infection (DMEM: C57BL/6 n=4, IL-6KO n=4) (LPS: C57BL/6
n=4, IL-6KO n=4) (CB3: C57BL/6 n=4, IL-6KO n=4) (CB3/LPS: C57BL/6 n=4, IL-6KO n=5). (B) The percent of CD4+ Treg cells was determined by
FACS of splenocytes at 3 and 7 days post DMEM, LPS, CB3 or CB3/LPS treatment. Treg cells were identified by expression of CD4 and the transcription
factor Foxp3. IL-6KO mice with DMEM treatment contained a significantly lower percentage of CD4+ Foxp3+ cells compared to the wild type controls
with DMEM treatment (DMEM: C57BL/6 n=8 at day 3 n=7 at day 7, IL-6KO n=8 at day 3 n=7 at day 7) (black bars indicate wt mice, white bars
indicate IL-6KO mice) (mean6SE, *p,0.05). However, following treatment with CB3 or CB3/LPS but not LPS alone, the percentage of CD4+ Foxp3+
cells was not significantly different (LPS: C57BL/6 n=8 at day 3 n=12 at day 7, IL-6KO n=8 at day 3 n=14 at day 7) (CB3: C57BL/6 n=8 at day 3 n=11
at day 7, IL-6KO n=8 at day 3 n=17 at day 7) (CB3/LPS: C57BL/6 n=9 at day 3 n=13 at day 7, IL-6KO n=9 at day 3 n=18 at day 7) (mean6SE,
*p,0.05) suggesting sufficient proportions of Treg cells are present to immunosuppress disease.
doi:10.1371/journal.pone.0006207.g002
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in IL-6KO mice
To characterize the changes following rIL-6 administration, we
monitored the cytokine milieu at day 3 PI. IL-6KO mice were
observed to have significantly increased serum levels of TNF-a, IL-
10, MCP-1, MIP-1b, MIG and RANTES compared to wild type
mice at 3 days post CB3/LPS treatment (Figure 6a and 6b). The
MIP-1a levels were also increased in the IL-6KO mice however
the increase was not significant. IL-6KO mice treated with rIL-6
during the early immune response following CB3/LPS infection
had significantly decreased serum levels of TNF-a, IL-10, MCP-1,
MIP-1b, MIG and RANTES as well as decreases in MIP-1a
(Figure 6a and 6b). This decreased early inflammatory response
correlated with decreased chronic disease severity at 28 days post
treatment (Figure 5a and 5b) and demonstrates that IL-6
production during the initiation of disease regulates the early
immune activation, which in turn determines the severity of
chronic disease.
In addition to changes in TNF-a and IL-10, the cytokines IFN-c
and IL-12p70 were differentially expressed between the wild type
and knockout mice. IL-12p70 was significantly increased in the IL-
6KO mice with and without rIL-6 treatment compared to wild
type controls while IFN-c was increased in the IL-6KO treated
with rIL-6 compared to wild type controls. While these increases
do not correlate with disease severity, it is possible that they may
be a mechanism of disease amelioration following rIL-6 treatment.
Increased cardiac infiltration in rIL-6 treated IL-6KO mice
As the chemokine production correlated with disease severity,
the immune cell infiltration in the heart was characterized at the
peak of the acute stage of disease (day 10 PI) in the wild type and
IL-6KO mice with and without rIL-6 treatment. As observed at
day 7 PI, IL-6KO mice treated with DMEM had significantly
increased CD11b+, CD11C2 macrophage/monocyte infiltration
compared to wild type controls at day 10 PI. Unexpectedly, while
treatment with rIL-6 resulted in decreased chemokine production,
increased cardiac infiltration was observed as increases in the
percentage of CD11b+CD11c2 and CD11b+CD11c+ monocyte/
macrophages and CD4+ and CD8+ T cells (Figure 7a, Figure
S4a). Specifically, the CD11b+CD11c2 monocyte/macrophage
Figure 3. TNF-a, IL-10 and MCP-1 expression is increased in the absence of IL-6. The serum concentrations of the cytokines IL-12p70, IL-6,
IL-10, IFNc, TNF-a and the chemokine MCP-1 were monitored following treatment with DMEM, LPS, CB3 and CB3/LPS by a BD cytometric bead array
inflammation assay (n$3 for each treatment group at day 1, 3 and 7, n$2 for each treatment group at day 14) (mean6SE, *p,0.05). IL-6 increased
following infection with CB3 indicating a role for IL-6 in the response to viral infection. TNF-a, IL-10 and MCP-1 were significantly increased in the IL-
6KO mice compared to the wild type controls indicating a possible role for IL-6 in the regulation of these immune components (orange diamonds
indicate DMEM treatment, green squares indicate LPS treatment, blue triangles indicate CB3 treatment, red circles indicate CB3/LPS treatment).
doi:10.1371/journal.pone.0006207.g003
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CD14 positive, while the CD11b+CD11c+ monocytes/macro-
phage population was 83.5%60.8% F4/80 positive and
81.0%63.2% CD14 positive.
Further, within the cardiac infiltrating CD4+ cell population at
day 10 PI, the proportion of Treg cells to CD4+ T cells did not
significantly differ between the wt and IL-6KO mice. IL-6KO mice
treated with rIL-6 had a significantly smaller proportion of CD4+
Tregs (Figure 7b, Figure S4b) despite a significantly greater number
of infiltrating CD4+ T cells. This suggests that Treg suppression is
not responsible for the decrease in inflammation and disease
observed in rIL-6 treated IL-6KO mice and that as expected, the
presence of IL-6 is reducing the proportion of Tregs to effector T
cells by day 10 PI. Interestingly, the IL-6 treatment results in a large
number of infiltrating lymphocytes, yet this is commensurate with
less observed pathology by day 28. Further, addition of rIL-6
decreased the regulationof the CD4+ T cell responsesand therefore
increases the adaptive immune response within the heart.
Additonally, minimal Th17 cells were found in wt or IL-6KO
mice, as measured by expression of the Th17 specific transcription
factor RORct at day 10 PI, regardless of the treatment (Figure 7b,
Figure S4b) suggesting that Th17 cells do not play a major
pathogenic role in viral-mediated autoimmune myocarditis
development.
Collectively, these results suggest that the four day administra-
tion of rIL-6 does not completely replicate the response of a wt IL-
6 replete mouse and instead is responsible for a change in the
make-up of the infiltrating cell population following infection (day
10) that is responsible for the control in the severity of late stage
chronic disease.
Discussion
Herein, we report that following coxsackievirus infection, IL-
6KO mice develop increased chronic autoimmune myocarditis.
This result is in contrast to previous reports that IL-6 deficient
mice were resistant to induction of autoimmune disease including
experimental-induced myocarditis [2]. The study of experimental-
induced disease lacks the complications of the viral infection and
the early immune response that is essential to specifically clear
virus from the host and is also responsible for triggering and
controlling a pluripotent autoreactive response.
Figure 4. IL-6KO mice have increased monocyte/macrophage
infiltration into the heart at 7 days post infection. Heart infiltrate
was measured by flow cytometry analysis at 7 days post treatment with
CB3/LPS. Cardiac infiltrate determined based on forward and side
scatter as well as CD11b and CD11c immunostaining. IL-6KO mice had
significantly increased monocyte/macrophage infiltration at 7 days post
treatment compared to wt mice (C57BL/6 n=9, IL-6KO n=11) (black
bars indicate wt mice, white bars indicate IL-6KO mice) (mean6SE,
*p,0.05). This increased correlated with the elevated levels of the
chemokine MCP-1 in IL-6KO mice and suggests a link between these
two factors.
doi:10.1371/journal.pone.0006207.g004
Figure 5. Injection of rIL-6 in IL-6KO mice decreased chronic disease severity following CB3/LPS treatment. (A) Representative
Masson’s Trichrome stained cardiac section from C57BL/6 or IL-6KO mice. Mice were treated with CB3/LPS and either DMEM or rIL-6 on days 0, 1, 2
and 3 post infection. Mice developed disease pathology as determined by fibrosis in blue and immune cell infiltration within the fibrosis areas by 28
days PI (C57BL/6 with DMEM n=15, IL-6KO with DMEM n=11, IL-6KO with rIL-6 n=9). Magnification:4006. (B) Chronic cardiac disease histology was
scored blindly by a four tier grading system to determine severity differences: grade 1, 0–10% pathology; grade 2, 11–25%; grade 3, 26–50%; grade 4,
greater than 50% (black circles indicate wt mice with DMEM, white circles indicate IL-6KO mice with DMEM, grey circles indicate IL-6KO mice with rIL-
6) (bar is mean6SE, *p,0.05). Disease severity was found to be decreased in the IL-6KO mice treated with rIL-6 compared to DMEM treated IL-6KO
mice.
doi:10.1371/journal.pone.0006207.g005
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myocarditis that correlated with changes in the early immune
response to virus infection. Most of the differences observed were
priortothepeakofvirusinfectionintheheartandclearancefromthe
animal. Specifically, we observed an increase in systemic cytokine/
chemokine production, splenic T cell activation and monocyte/
macrophageinfiltrationintheheart.Thisheighteneddiseaseseverity
was not due to aninabilityto control viral replication as there wasno
Figure 6. Injection of rIL-6 in IL-6KO mice decreased early
inflammatory responses at 3 days post infection. (A) The serum
concentrations of the cytokines IL-12p70, IL-6, IL-10, IFNc and TNF-a
were monitored following treatment with CB3/LPS by a BD cytometric
bead array inflammation assay at day 3 PI (C57BL/6 with DMEM n=10,
IL-6KO with DMEM n=9, IL-6KO with rIL-6 n=10) (black bars indicate wt
mice with DMEM, white bars indicate IL-6KO mice with DMEM, grey bars
indicate IL-6KO mice with rIL-6) (mean6SE, *p,0.05). TNF-a, IL-10 and
IL-12p70 levels were significantly increased in the IL-6KO mice
compared to wild type controls. rIL-6 treatment was sufficient to
decrease the serum concentration of IL-10 and TNF-a.( B) The serum
concentrations of the chemokines MCP-1, MIP-1a, MIP-1b, MIG and
RANTES were monitored following treatment with CB3/LPS by a BD
cytometric bead array flex set assay at day 3 PI (C57BL/6 n=10, IL-6KO
with DMEM n=9, IL-6KO with rIL-6 n=10) (black bars indicate wt mice
with DMEM, white bars indicate IL-6KO mice with DMEM, grey bars
indicate IL-6KO mice with rIL-6) (mean6SE, *p,0.05). All chemokine
levels were increased in the IL-6KO mice compared to wild type
controls. Treatment with rIL-6 was sufficient to decrease the levels of all
the chemokines.
doi:10.1371/journal.pone.0006207.g006
Figure 7. rIL-6 injection in IL-6KO mice increased innate and
adaptive immune cell infiltration in the heart. (A) Heart infiltrate
was measured by flow cytometry analysis at 10 days post treatment
with CB3/LPS with or without rIL-6 treatment. Cardiac infiltrate was
stained to determine innate and adaptive immune cell infiltration using
the surface markers CD11b, CD11c, CD3, CD4 and CD8. rIL-6 treatment
in the IL-6KO mice resulted in increased monocyte/macrophages
(CD11b+CD11c2 and CD11b+CD11c+), CD4+ T cells (CD3+CD4+) and
CD8+ T cells (CD3+CD8+) at 10 days post treatment compared to wt
and IL-6KO mice treated with DMEM (C57BL/6 with DMEM n=14, IL-
6KO with DMEM n=10, IL-6KO with rIL-6 n=11) (black bars indicate wt
mice with DMEM, white bars indicate IL-6KO mice with DMEM, grey bars
indicate IL-6KO mice with rIL-6) (mean6SE, *p,0.05). (B) The percent of
CD4+ cells that are Treg or Th17 cells was determined by flow
cytometry analysis of cardiac infiltrate at 10 days post CB3/LPS
treatment. Treg cells were identified by the presence of the surface
marker CD4 and the transcription factor Foxp3 while Th17 cells were
identified by the presence of the surface marker CD4 and the
transcription factor RORct. rIL-6 treated IL-6KO mice contained a
significantly lower percentage of CD4+ cells that were Treg cells
compared to the DMEM treated wild type controls and DMEM treated
IL-6KO mice. Minimal Th17 cells were observed in the heart regardless
of treatment (C57BL/6 with DMEM n=7, IL-6KO with DMEM n=9, IL-
6KO with rIL-6 n=8) (black bars indicate wt mice with DMEM, white
bars indicate IL-6KO mice with DMEM, grey bars indicate IL-6KO mice
with rIL-6) (mean6SE, *p,0.05).
doi:10.1371/journal.pone.0006207.g007
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Further indicating a regulatory role for IL-6, rIL-6 treatment during
the early immune response was sufficient to decrease the early
inflammatory response with a corresponding decrease in the chronic
disease.TheseresultsstronglysuggestthatIL-6regulatesandcontrols
the initial host response to pathogen insult and that absence of IL-6
early post infection leaves the host susceptible to increased long-term
complications of autoimmune myocarditis.
IL-6 has a pathogenic role in experimental autoimmune models
such as EAM [2], EAE [11], pristane-induced lupus [12],
experimental-induced arthritis [13,14] and autoimmune myasthe-
nia gravis [15]. Mice deficient in this cytokine were resistant to
autoimmune disease development [2,11,12,13,14,15]. Our results,
however, clearly show induction of chronic disease with height-
ened severity in the absence of IL-6. Therefore, viral induction of
disease follows a different disease pathogenesis with a more
complex immune response in which cytokines, such as IL-6, have
varied specific roles compared to experimental models of
autoimmunity. Our results suggest a regulatory role for IL-6
following viral infection. Previously, the addition of recombinant
IL-6 following encephalomyocarditis virus (EMCV) infection
resulted in a decrease in disease severity of autoimmune
myocarditis [3]. However, EMCV infection in mice which
overexpress IL-6 leads to increased disease severity [5]. These
results and ours suggest that IL-6 functions in a delicate balance as
a regulator. Early after infection, IL-6 acts to dampen the strength
of initial anti-viral immune response to reduce the risk of
developing autoimmunity, however, its long-term presence as a
chronic participant leads to heightened chronic disease.
Specifically, IL-6 is an essential participant in the acute phase
response following viral infection. IL-6 deficient mice were unable
to control infection by vaccinia virus and lymphocytic choriomen-
ingitis virus (LCMV) [6,19]. In terms of CB3, an inability to control
the viral infection would lead to greater viral and host directed
cardiac damage and subsequently increase chronic disease. We
observed no differences in the quantity of replicative virus between
the hearts of IL-6KO and wt mice post infection. This suggests that
the ability of IL-6 deficient hosts to control CB3 replication was not
an issue. Our data suggests that for CB3 infection, the increase in
diseaseseverityis a consequenceof a dysregulatedimmune response
due to lack of IL-6 throughout the process.
Our results suggest that IL-6 functions by regulating the balance
of cytokines and chemokines during the early host response to
infection. Thus, IL-6 control has both local and systemic
implications and greatly differentiates disease outcome. Changes
in the cytokine milieu in the early immune response (day 3 PI)
following infection have been demonstrated to later influence the
development of chronic autoimmunity [20].
IL-10 levels were found to be increased in the IL-6KO mice. As
IL-10 is associated with the anti-inflammatory response and T cell
suppression [21] this was a surprising observation. Produced
primarily by monocytes and macrophages, IL-10 functions to
decrease pro-inflammatory cytokine production by APCs [22].
Production of pro-inflammatory cytokines and IL-10 are initiated
following the same stimuli in a cell intrinsic manner and this acts to
regulate the inflammatory immune response [22]. Therefore, the
early upregulation of IL-10 may serve to control the increased
inflammatory cytokines produced in the absence of IL-6. The
window of IL-10 expression is short and also observed to be
upregulated by LPS treatment alone. In experimental models of
autoimmunity including EAE and EAM, IL-10 suppresses disease
severity [23,24]. In contrast, it has been suggested that increased
IL-10 following CB3 infection in human monocytes leads to a
dysregulation of the immune response to the virus and ultimately
allows for the progression to the chronic disease [25]. In fact,
increased levels of IL-10 in human patients with fulminant
myocarditis correlates with increased mortality rates [26]. IL-10 is
also increased in mice following CB3 infection and was again
suggested to allow for disease progression from the acute stage of
disease to the chronic stage of disease [27,28]. As such, the
increased IL-10 may play a role in increased disease severity.
These results highlight the complex balance of pro- and anti-
inflammatory mechanisms that are regulated by IL-6.
The increases in TNF-a and MCP-1 observed in the infected
IL-6 deficient mice represent a heightened inflammatory response.
Both TNF-a and MCP-1 have previously been associated with
both disease development and severity, and likely contribute to the
increased disease pathology. TNF-a has been instrumental in
overcoming genetic resistance to CB3-mediated autoimmune
myocarditis [29] and likely acts downstream of LPS signaling.
TNF-a was sufficient to induce spontaneous autoimmune
myocarditis in mice constitutively overexpressing this cytokine in
the heart [30]. In patients with enteroviral-induced myocarditis,
TNF-a levels are often increased and are associated with increased
myocardial necrosis and cellular infiltration in the myocardium
[31]. In our model, TNF-a levels were associated with increased
disease severity. In wt mice, similar TNF-a levels were attained
following treatment with CB3/LPS or LPS alone regardless of
disease outcome suggesting that TNF-a levels are not sufficient for
disease observed in these mice. In the absence of IL-6, the level of
TNF-a increased with CB3/LPS and was associated with
heightened disease severity, clearly indicating a role for TNF-a
as an important inflammatory co-factor in disease progression.
Taken together, TNF-a functions to increase inflammation
associated with the induction of autoimmune heart disease and
in the absence of IL-6, an imbalance of TNF-a is induced during
the viral response resulting in heightened disease pathology.
MCP-1 is a potent chemoattractant for mononuclear cells, T cells
and NK cells expressing CCR2, the receptor for MCP-1, on their
surface [18,32]. MCP-1 is secreted by endothelial cells [33], muscle
cells [34] and most notably, coxsackievirus infected cardiac
myocytes [18]. Further, elevated MCP-1 expression has been
correlated with immune cell infiltration in the heart following
coxsackievirus infection [18]. MCP-1 is expressed in a dose
dependent manner during coxsackievirus infection [18] and
increases over the course of infection thus suggesting that it benefits
the host response to CB3 infection. Further, mice deficient in MCP-
1 or CCR2 are resistant to the development of experimental-
induced autoimmune myocarditis [35]. Heart specific expression of
MCP-1 is sufficient to induce monocyte/macrophage migration to
the heart leading to myocarditis and fibrosis [36]. This suggests that
MCP-1 and the migration of monocytes/macrophages to the heart
is integral to the developing cardiac lesions.
In our model, the absence of IL-6 results in increased early
expression of MCP-1 associated with increased monocyte/macro-
phage infiltration during both the acute infection and the later
chronic stage of disease. In the absence of IL-6, this increase in
mononuclear cell migration to the heart could lead to heightened
cardiopathology. Increased levels of macrophages and monocytes
could lead to greater levels of uncontrolled damage and lesion
development without a concomitant increase in viral replication or
viral directed pathology. However, the further increase in heart
infiltrate following rIL-6 treatment would suggest that this is not the
mechanism of increased disease severity. In support, increased
macrophage infiltration in the heart was seen with rIL-6 treatment
following EMCV infection in correlation with decreased chronic
disease pathology [3]. It was suggested that the increased
macrophage infiltration could lead to faster clearance of virus and
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observed increased innate and adaptive immune cell infiltration in
combination with a decreased cytokine inflammatory response. It is
likely that this combination results in faster viral clearance and
better regulation of the early inflammatory responses and results in
decreased chronic disease severity in these rIL-6 treated mice. Since
it is likely that both viral and immune directed damage are
controlling the outcome, the lack of IL- 6 results in slower clearance
with less regulation of the early inflammatory responses leading to
more inflammatory activity in the heart and results in heightened
chronic disease and cardiac damage.
We provide evidence that IL-6 acts to regulate the early
immune response following coxsackievirus infection. Regulation of
the early response in turn controls the severity of the subsequent
chronic disease pathology. Immune factors associated with the
increased disease severity included early T cell activation and
inflammatory cytokine and chemokine responses following disease
induction. Without IL-6 to regulate the early immune response
after infection, the heightened early inflammatory response leads
to increased chronic myocarditis severity as the disease progresses.
These results suggest that, contrary to what was suggested by
results from experimental models of disease, anti-IL-6 treatment
following viral-induced myocarditis could result in increased
damage to the host.
Supporting Information
Figure S1 IL-6KO mice have increased expression of the early
activation marker CD69 at 3 days PI. (A) Representative flow
cytometry analysis of splenocyte T cell activation at 3 days post
DMEM, LPS, CB3 or CB3/LPS treatment. Activated T cells were
identified by immunostaining to the surface markers CD4, CD8
and CD69. CD69 expression was significantly increased on both
CD4+ and CD8+ T lymphocytes at 3 days post infection (DMEM:
C57BL/6 n=4, IL-6KO n=4) (LPS: C57BL/6 n=7, IL-6KO
n=8) (CB3: C57BL/6 n=8, IL-6KO n=18) (CB3/LPS: C57BL/
6 n=8, IL-6KO n=17) (grey line indicate wt mice, black line
indicate IL-6KO mice, light grey area indicates isotype control).
(B) Representative flow cytometry analysis of splenocyte T cell
activation at 7 days post DMEM, LPS, CB3 or CB3/LPS
treatment. Activated T cells were identified by immunostaining to
the surface markers CD4, CD8 and CD69. CD69 expression was
not significantly different on both CD4+ and CD8+ T lympho-
cytes at 7 days post infection (DMEM: C57BL/6 n=4, IL-6KO
n=4) (LPS: C57BL/6 n=4, IL-6KO n=4) (CB3: C57BL/6
n=4, IL-6KO n=4) (CB3/LPS: C57BL/6 n=4, IL-6KO n=5)
(grey line indicate wt mice, black line indicate IL-6KO mice, light
grey area indicates isotype control).
Found at: doi:10.1371/journal.pone.0006207.s001 (0.20 MB TIF)
Figure S2 IL-6KO mice have decreased regulatory T cells. (A)
Representative flow cytometry analysis of splenocyte regulatory T
cells 3 days post DMEM, LPS, CB3 or CB3/LPS treatment. Treg
cells were identified by immunostaining for expression of CD4 and
the transcription factor Foxp3. IL-6KO mice contained a
significantly lower percentage of CD4+ Foxp3+ cells compared
to the wild type controls with DMEM treatment (DMEM:
C57BL/6 n=8, IL-6KO n=8). However, following treatment
with CB3 or CB3/LPS but not LPS alone, the percentage of
CD4+ Foxp3+ cells was not significantly different (LPS: C57BL/6
n=8, IL-6KO n=8) (CB3: C57BL/6 n=8, IL-6KO n=8) (CB3/
LPS: C57BL/6 n=9, IL-6KO n=9) (grey line indicate wt mice,
black line indicate IL-6KO mice, light grey area indicates isotype
control) suggesting sufficient proportions of Treg cells are present
to immunosuppress disease. (B) Representative flow cytometry
analysis of splenocyte regulatory T cells 7 days post DMEM, LPS,
CB3 or CB3/LPS treatment. Treg cells were identified by
immunostaining to surface CD4 and the transcription factor
Foxp3. IL-6KO mice contained a significantly lower percentage of
CD4+ Foxp3+ cells compared to the wild type controls with
DMEM treatment (DMEM: C57BL/6 n=7, IL-6KO n=7).
However, following treatment with CB3 or CB3/LPS but not LPS
alone, the percentage of CD4+ Foxp3+ cells was not significantly
different (LPS: C57BL/6 n=12, IL-6KO n=14) (CB3: C57BL/6
n=11, IL-6KO n=17) (CB3/LPS: C57BL/6 n=13, IL-6KO
n=18) (grey line indicate wt mice, black line indicate IL-6KO
mice, light grey area indicates isotype control).
Found at: doi:10.1371/journal.pone.0006207.s002 (0.65 MB TIF)
Figure S3 IL-6KO mice have an increased number of
monocyte/macrophage cells in the heart at 7 days post infection.
Heart infiltrate was measured by flow cytometry analysis at 7 days
post treatment with CB3/LPS. Cardiac infiltrate was determined
based on forward and side scatter as well as CD11b and CD11c
immunostaining. IL-6KO mice had significantly increased mono-
cyte/macrophage infiltration at 7 days post treatment compared to
wt mice (C57BL/6 n=9, IL-6KO n=11) (black bars indicate wt
mice, white bars indicate IL-6KO mice) (mean6SE, *p,0.05).
Found at: doi:10.1371/journal.pone.0006207.s003 (0.19 MB TIF)
Figure S4 rIL-6 injection in IL-6KO mice increased the number
of innate and adaptive immune cells infiltrating in the heart at 10
days post infection. (A) Heart infiltrate was measured by flow
cytometry analysis at 10 days post treatment with CB3/LPS with or
without rIL-6 treatment. Cardiac infiltrate was immunostained to
determine innate and adaptive immune cell infiltration using the
surface markers CD11b, CD11c, CD3, CD4 and CD8. rIL-6
treatment in the IL-6KO mice resulted in increased numbers of
monocyte/macrophages (CD11b+CD11c2 and CD11b+CD11c+),
CD4+ Tc e l l s( C D 3 +CD4+) and CD8+ Tc e l l s( C D 3 +CD8+)a t1 0
days post treatment compared to wt mice (C57BL/6 with DMEM
n=9, IL-6KO with DMEM n=8, IL-6KO with rIL-6 n=7) (black
bars indicate wt mice with DMEM, white bars indicate IL-6KO
mice with DMEM, grey bars indicate IL-6KO mice with rIL-6)
(mean6SE, *p,0.05). (B) The number of Treg and Th17 cells was
determined by flow cytometry analysis of cardiac infiltrate at 10 days
post CB3/LPS treatment. Treg cells were identified by immuno-
staining for the presence of the surface marker CD4 and the
transcription factor Foxp3 while Th17 cells were identified by
immunostaining for the presence of the surface marker CD4 and the
transcription factor RORct. rIL-6 treated IL-6KO mice contained a
significantly higher number of Treg cells compared to the DMEM
treated wild type controls and DMEM treated IL-6KO mice.
Minimal Th17 cells were observed in the heart regardless of
treatment (C57BL/6 with DMEM n=7, IL-6KO with DMEM
n=9, IL-6KO with rIL-6 n=8) (black bars indicate wt mice with
DMEM, white bars indicate IL-6KO mice with DMEM, grey bars
indicate IL-6KO mice with rIL-6) (mean6SE, *p,0.05).
Found at: doi:10.1371/journal.pone.0006207.s004 (0.25 MB TIF)
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